• Date:

Valuation in Life Sciences Workshop

Valuation in Life Sciences Workshop at EPFL Innovation Park:

“Knowing the value of your startup could be a real advantage when talking to potential investors”

September 9th, 2016, 8h30-12h30 – Room Uranus (Build.D)


The valuation of an early stage company is a central matter to both investors and founders. However, valuation of early stage companies is a challenge given the lack of historical data, little or no revenues, operating losses and many uncertain factors about the future (survival rate,…). This workshop will present more than one methodology compiled from several sources for the valuation of early stage high-tech (life sciences) companies.
Starting with the future cash flows from the business plan of a start-up, a DCF valuation gives the company value. The beta coefficient is then discussed and adjusted representing the individual risks.  Other considerations (such as potential exit strategies – out-licensing, asset sale,…) are also brought in and alternative valuation methods are presented, like the ones used by venture capital investors.

In just 4 hours, you will have enough tools to start the valuation of your own company!

The workshop will be held in English, however questions could be asked in English, French or Italian.
Limited to 20 participants: CEO, CFO, Business development director


Bio of the Workshop leader: Pascale Boyer Barresi, CFA

pascale boyer barresi
Pascale Boyer Barresi is a Senior Manager for Advisory Deals focused on Swiss Life Sciences Companies at PricewaterhouseCoopers in Geneva. She has a broad expertise in life sciences project and portfolio valuation, market and competition analysis as well as financial modelling.
Pascale had an extended experience in finance (MSCI, Bordier & Cie) as equity analyst for Pharma, Biotech & Medtech companies and fund manager for Swiss Equities. Moving on to the pharmaceutical industry in 2010, she successfully developed and implemented the sales forecasting methodology and project valuation systems at Debiopharm International. She was also responsible for the business plan analysis, stress-testing company and portfolio valuation at Debiopharm Diagnostics (private equity). She joined PwC in 2016.
Pascale holds a Business Economics Master’s Degree from University of Fribourg. She is a CFA charterholder since 2003. She also completed additional education in Pharmaceutical Economics and Policy at the University of Lausanne as well as Health Technology Assessments Certificate at SBA Bocconi and Digital Communication, Social Media & Web Expertise at the University of Geneva. Pascale’s native language is French and she is fluent in English and Italian.
For more information check out her LinkedIn Profile or her blog on Life Sciences: https://digital-pillbox.com/


Thanks to include complete contact details, company name and your function.
Don’t wait too long, first come = first served!

Björn Ignell
Marketing & Course Manager – CTI Entrepreneurship Suisse-Romande
Mobile +41 78 603 35 08 ● Reception : +41 21 353 80 00